nach oben

Osteoporosis International

Erschienen in:

02.09.2017 | Case Report

Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG)

verfasst von: M. Celli, P. D’Eufemia, P. Persiani, A. Turchetti, A. Febbo, Y. D’Alfonso, L. Celli, A. Zambrano

Erschienen in: Osteoporosis International | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Osteoporosis-pseudoglioma syndrome (OPPG) is a rare autosomal recessive syndrome characterized by juvenile-onset osteoporosis and ocular abnormalities due to a low-density lipoprotein receptor-related protein 5 (LRP5) gene mutation. Treatment with bisphosphonates, particularly with pamidronate and risedronate, has been reported to be of some efficacy in this condition. We report on a patient with OPPG due to an LRP5 gene mutation, who showed an encouraging response after a 36-month period of neridronate therapy. We report a case of a patient treated with bisphosphonates. Bisphosphonates should be administered in OPPG patients as a first-line therapy during early childhood.

Ai M, Heeger S, Bartels CF, Schelling DK (2005) Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet 77:741–753CrossRefPubMedPubMedCentral

Gong Y, Vikkula M, Boon L (1996) Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet 59:146–151PubMedPubMedCentral

Somer H, Palotie A, Somer M, Hoikka V, Peltonen L (1988) Osteoporosis-psedudoglioma syndrome: clinical, morphological and biochemical studies. J Med Genet 25:543–549CrossRefPubMedPubMedCentral

Frontali M, Dallapiccola B (1986) Osteoporosis-pseudoglioma syndrome and the ocular form of osteogenesis imperfect. Clin Genet 29:262CrossRefPubMed

Lev D, Binson I, Foldes AJ, Watemberg N, Lerman-Sagie Y (2003) Decreased-bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome. Isr Med Assoc J 5:419–421PubMed

Gong Y, Slee RB, Fukai N, Warman ML (2001) Osteoporosis-pseudoglioma syndrome collaborative group: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523CrossRefPubMed

Streeten EA, McBride D, Puffenberger E, Hoffman ME, Pollin TI, Donelly P, Sack P, Morton H (2008) Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone 43:584–590CrossRefPubMedPubMedCentral

Zacharin M, Cundy T (2000) Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr 137:410–415CrossRefPubMed

Levasseur R (2008) Treatment and management of osteoporosis-pseudoglioma syndrome. Expert Rev Endocrinol Metab 3:337–348CrossRef

10.

Gatti D, Rossini M, Viapiana O, Idolazzi L, Adami S (2013) Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag 9:139–147CrossRefPubMedPubMedCentral

11.

Adami S, Bevilacqua M, Broggini M, Filipponi P, Ortolani S, Palummeri E, Ulivieri F, Nannipieri F, Braga V (2002) Short-term intravenous therapy with neridronate in Paget’s disease. Clin Exp Rheumatol 20:55–58PubMed

12.

Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfect: a randomized controlled study. J Bone Miner Res 20:758–763CrossRefPubMed

13.

D’Eufemia P, Finocchiaro R, Zambrano A, Lodato V, Celli L, Finocchiaro S, Persiani P, Turchetti A, Celli M (2017) Serum creatine kinase isoenzymes in children with osteogenesis imperfect. Osteoporos Int 28:339–346CrossRefPubMed

14.

Laine CM, Chung BD, Susic M, Prescott T, Semler O, Fiskerstrand D’EP, Castori M, Pekkinem M, Sochett E, Cole WG, Netzer C, Makitie O (2011) Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur J Hum Genet 19:875–881CrossRefPubMedPubMedCentral

15.

Alonso N, Soares DC, McCloskey EV, Summers GD, Raltston SH, Gregson CL (2015) Atypical femoral fracture in osteoporosis pseudoglioma syndrome associated with two novel compound heterozygous mutations in LRP5. J Bone Miner Res 30(4):615–620CrossRefPubMed

16.

Yadav VK, Ducy P (2010) LRP5 and bone formation. A serotonin-dependent pathway. Ann N Y Acad Sci 1192:103–109CrossRefPubMed

17.

Toomes C, Bottomley HM, Jackson RM et al (2004) Mutations in LRP5 of FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet 74:721–730CrossRefPubMedPubMedCentral

18.

Di Iorgi N, Maghnie M (2006) Motor function improvement after intravenous pamidronate in osteoporosis pseudoglioma syndrome. J Pediatr 149:734CrossRefPubMed

19.

Bayram F, Tansiverdi F, Kurtoglu S, Atabek ME, Kula M, Kaynar L, Kelestimur F (2006) Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG). J Pediatr Endocrinol Metab 19:275–279CrossRefPubMed

20.

Barros ER, Dias da Silva MR, Kunii IS, Lazaretti-Castro M (2008) Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab 21:911CrossRef

21.

Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M (2011) Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. J Bone Miner Res 26:2823–2826CrossRefPubMed

Titel: Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG)
verfasst von: M. Celli
P. D’Eufemia
P. Persiani
A. Turchetti
A. Febbo
Y. D’Alfonso
L. Celli
A. Zambrano
Publikationsdatum: 02.09.2017
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 11/2017
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-017-4214-x

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG)

Abstract

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Comparison of spinal alignment, muscular strength, and quality of life between women with postmenopausal osteoporosis and healthy volunteers

Impact of SIGN guideline thresholds for DXA access for patients referred to direct access DXA: implications for clinical practice?

Musculoskeletal health in newly diagnosed children with Crohn’s disease

Impact of pioglitazone on bone mineral density and bone marrow fat content

Atypical femur fractures: a survey of current practices in orthopedic surgery

24-hour profile of serum sclerostin and its association with bone biomarkers in men

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Update Orthopädie und Unfallchirurgie